Join the Aripiprazole group to help and get support from people like you.
Aripiprazole News
Long-Acting Injected Antipsychotics Help People With Schizophrenia Stay Out of Hospital
WEDNESDAY, Jan. 31, 2024 – For people with schizophrenia hospitalized after a psychotic episode, getting a long-acting antipsychotic injection works far better than pills to keep them from returning...
FDA Approves Abilify Asimtufii (aripiprazole) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults
April 28, 2023 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA)...
FDA Approves Aristada Initio (aripiprazole lauroxil) for the Initiation of Aristada for Schizophrenia
DUBLIN, July 2, 2018 /PRNewswire/ – Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved Aristada Initio (aripiprazole lauroxil) for the...
FDA Approves Abilify MyCite (aripiprazole) Pill with Sensor to Digitally Track if Patients Have Ingested Their Medication
November 13, 2017 – The U.S. Food and Drug Administration today approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an...
Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension Approved by the U.S. FDA for Maintenance Monotherapy Treatment of Bipolar I Disorder
Valby, Denmark and Tokyo, Japan, 28 July 2017 - H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced Abilify Maintena® (aripiprazole) for extended-release ...
FDA Approves Two-Month Aristada for Treatment of Schizophrenia
DUBLIN--(BUSINESS WIRE)--Jun. 6, 2017-- Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved two-month Aristada (aripiprazole lauroxil)...
FDA Medwatch Alert: Aripiprazole (Abilify, Abilify Maintena, Aristada): Drug Safety Communication - FDA Warns About New Impulse-control Problems
ISSUE: FDA is warning that compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex have been reported with the use of the antipsychotic drug aripiprazole (Abilify, Abilify...
FDA Approves Aristada (aripiprazole lauroxil) for Schizophrenia
October 6, 2015 – On October 5, the U.S. Food and Drug Administration approved Aristada (aripiprazole lauroxil) extended release injection to treat adults with schizophrenia. Aristada is...
FDA Approves Labeling Update Of Abilify Maintena for Acutely Relapsed Adults With Schizophrenia
Tokyo, Japan and Valby, Denmark – December 6, 2014 – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced that the U.S. Food and Drug Administration (FDA) approved the lab...
FDA Approves Dual-Chamber Syringe for Abilify Maintena (aripiprazole) for Schizophrenia
Princeton, N.J. and Deerfield, Ill. – September 29, 2014 – Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka) and Lundbeck announced today that the U.S. Food and Drug Administration ...
FDA Approves Once-Monthly Abilify Maintena (aripiprazole) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia
TOKYO & COPENHAGEN, Denmark--(BUSINESS WIRE)--Feb 28, 2013 - Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved...
U.S. Food and Drug Administration Approves Abilify (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)
PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Nov 20, 2009 - Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved...
Further information
Related condition support groups
Bipolar Disorder, Autism, Agitated State, Depression, Borderline Personality Disorder, Schizophrenia, Major Depressive Disorder, Obsessive Compulsive Disorder, Post Traumatic Stress Disorder, Schizoaffective Disorder